Artificial Intelligence company NotCo unveiled plans for a potential new product, a GLP-1 booster, claiming it to function as a "natural alternative" to Ozempic.
NotCo, a Chilean food tech startup, has announced the development of a groundbreaking product called the GLP Booster. This innovative solution aims to serve as a natural alternative to Ozempic, a popular GLP-1 hormone-based medication used for weight loss and blood sugar regulation.
The GLP Booster, set to launch this year, mimics the effects of the GLP-1 hormone, helping to regulate blood sugar levels, induce satiety, and manage weight. NotCo's creation is not a drug or synthetic agonist, but a new category of food-driven metabolic enhancement.
The market for weight-loss drugs, including GLP-1 agonists, is projected to reach $105 billion by the end of the decade. With one in five children and adolescents in the US being obese, and approximately three-quarters of Americans aged 20 and above being overweight or obese, there is a significant need for effective and natural solutions.
NotCo's GLP Booster is aimed at individuals who are apprehensive about the side effects of GLP-1 drugs and the 'Ozempic rebound'. This rebound occurs when, after quitting a GLP-1 medication, a net 30% of people may eat more calories than before, leading to weight regain. On average, Ozempic users regain two-thirds of their weight one year after quitting.
Matias Muchnick, co-founder and CEO of NotCo, emphasised the importance of maintaining long-term metabolic health. While GLP-1 drugs reduce caloric intake, they don't distinguish between fat loss and muscle loss, which is crucial for long-term metabolic health.
The GLP Booster is a powder that can be added to food to stimulate GLP-1 production and block enzymes that break down the hormone. NotCo plans to launch the GLP Booster into packaged snacks, shakes, and ready meals. It will also be sold as a powdered blend that can be added to pasta, smoothies, and as an ingredient for food manufacturers.
In addition to NotCo's efforts, California's One Bio recently raised $27M for its technology that extracts fibres from plants for use in GLP-1-friendly foods. Scientists at Spain's Catholic University of Murcia have also discovered plant extracts that could potentially be used to make GLP-1 agonist pills.
As the demand for GLP-1 agonist drugs like Ozempic, Wegovy, and Mounjaro is projected to reach between 10 to 70 million by 2028, natural alternatives like NotCo's GLP Booster could provide meaningful benefits to individuals who cannot access these medications.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
